Premedication and incidence of infusion-related reactions in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan-based chemotherapy. Background: Peri-operative ...

Ascorbic acid plus gemcitabine (gem) and erlotinib (erl) in patients with metastatic pancreatic cancer (mPanc): Preliminary safety results. Background: To evaluate the toxicity focussing on hepatic, ...

In this review we will discuss TACE, TAE and TOCE in detail. The TACE procedure consists of the injection of anticancer drugs mixed with or without lipiodol into the hepatic artery followed by the ...

Introduction: In patients with inoperable intrahepatic cholangiocarcinoma (ICC), both conventional transarterial chemoembolization (cTACE) and drug-eluting bead TACE (DEB-TACE) can be employed as ...

Please provide your email address to receive an email when new articles are posted on . Taking Decadron combined with Emend prior to drug eluting bead transarterial chemoembolization helped prevent ...

Please note - this trial is no longer recruiting patients. We hope to add results when they are available. There are a number of different treatments for liver cancer. One treatment is called trans ...

Please provide your email address to receive an email when new articles are posted on . BTG received Class III CE Mark certification for its DC Bead LUMI, a radiopaque drug-eluting bead for patients ...

DC Bead LUMI™ Radiopaque Drug-Eluting Bead Offers Interventional Radiologists in Canada a Next Generation Treatment Option for Liver Cancer Patients OTTAWA, Dec. 5, 2016 /CNW/ - BTG International ...

BTG plc, a global specialist healthcare company, has received Class III CE Mark certification for DC Bead LUMI the first commercially available radiopaque drug-eluting bead (DEB) in the EU which can ...

BTG International Canada Inc. received Health Canada approval for DC Bead LUMI TM in August, 2016. DC Bead LUMI™ is the first available radiopaque embolic drug-eluting bead that can be loaded with ...